Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Director | June 07, 2023 | June 09, 2023 |
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | Director | June 15, 2022 | June 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.83 · Expires 2033-06-07 | Direct | 16,000 |
Reported balance
After 2023-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 16,000 · Balance 16,000 F1: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders.
Eloxx Pharmaceuticals, Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2032-06-15 | Direct | 20,000 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. F2: The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter.
F2: The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2023 Filed Jun 9, 2023 16:56 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $12.83 | $0.00 |
DisclosureSEC source: 0000899243-23-015205 · doc4.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:27 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072185 · tm2218714-4_4seq1.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. F2 · balance_after: The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 17:09 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $13.72 | $0.00 |
DisclosureSEC source: 0000899243-22-023131 · doc4.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 19:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042080 · doc4.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-10-27 F1 · derivative.exercise_date: The shares underlying this option vest as follows: These shares will vest in full on October 28, 2022. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:11 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 3,334 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002615 · form4-05202021_040542.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. Read SEC document |
| May 13, 2021 Filed May 17, 2021 13:22 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 2,381,890 | $1.35 | $3,215,551.50 |
DisclosureSEC source: 0001104659-21-067516 · tm2116620d4_4.xml · nonDerivative · entry 2 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,827,129 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F3 · ownership.nature: Held directly by Advent Life Sciences Fund II LP. Advent Life Sciences LLP is the manager of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 13, 2021 Filed May 17, 2021 13:22 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 84,776 | $1.35 | $114,447.60 |
DisclosureSEC source: 0001104659-21-067516 · tm2116620d4_4.xml · nonDerivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 171,807 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F2 · ownership.nature: Held directly by Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:33 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001415889-21-001896 · form4-04052021_050420.xml · derivative · entry 3 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-04-01 F5 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one-half (1/2) of the shares underlying the option shall vest on April 1, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:33 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantCommon Stock | 2,445,239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-001896 · form4-04052021_050420.xml · nonDerivative · entry 2 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,445,239 F3 · price: Received by Advent Life Sciences Fund II LLP in exchange for 9,715,135 Series A Preferred and 37,139,650 Series A-1 Preferred shares of Zikani in connection with the acquisition of Zikani by the Issuer. F4 · ownership.nature: Held directly by Advent Life Sciences Fund II LLP. Advent Life Sciences LLP is the manager of Advent Life Sciences Fund II LLP and the Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:33 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantCommon Stock | 87,031 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-001896 · form4-04052021_050420.xml · nonDerivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 87,031 F1 · price: Received by Advent Life Sciences LLP in exchange for 345,785 Series A Preferred and 1,321,888 Series A-1 Preferred shares of Zikani Therapeutics, Inc. ("Zikani") in connection with the acquisition of Zikani by the Issuer. F2 · ownership.nature: Held directly by Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.